Switch theme
Sign up to access all valuation multiples
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
2013
393
LTM Revenue $39.4M
LTM EBITDA -$448M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CRISPR Therapeutics has a last 12-month revenue (LTM) of $39.4M and a last 12-month EBITDA of -$448M.
In the most recent fiscal year, CRISPR Therapeutics achieved revenue of $35.0M and an EBITDA of -$447M.
CRISPR Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CRISPR Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $39.4M | XXX | $35.0M | XXX | XXX | XXX |
| Gross Profit | $37.3M | XXX | -$75.3M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | -215% | XXX | XXX | XXX |
| EBITDA | -$448M | XXX | -$447M | XXX | XXX | XXX |
| EBITDA Margin | -1137% | XXX | -1278% | XXX | XXX | XXX |
| EBIT | -$493M | XXX | -$467M | XXX | XXX | XXX |
| EBIT Margin | -1252% | XXX | -1333% | XXX | XXX | XXX |
| Net Profit | -$405M | XXX | -$366M | XXX | XXX | XXX |
| Net Margin | -1028% | XXX | -1046% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CRISPR Therapeutics's stock price is $36.
CRISPR Therapeutics has current market cap of $3.1B, and EV of $1.5B.
See CRISPR Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $3.1B | XXX | XXX | XXX | XXX | $-4.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CRISPR Therapeutics has market cap of $3.1B and EV of $1.5B.
CRISPR Therapeutics's trades at 42.8x EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate CRISPR Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CRISPR Therapeutics has a P/E ratio of -7.7x.
See valuation multiples for CRISPR Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 38.0x | XXX | 42.8x | XXX | XXX | XXX |
| EV/EBITDA | -3.3x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -3.0x | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | 40.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -8.6x | XXX | XXX | XXX |
| EV/FCF | -6.6x | XXX | -10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCRISPR Therapeutics's last 12 month revenue growth is 143%
CRISPR Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
CRISPR Therapeutics's rule of 40 is 88% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CRISPR Therapeutics's rule of X is -778% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CRISPR Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 143% | XXX | 121% | XXX | XXX | XXX |
| EBITDA Margin | -1137% | XXX | -1278% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 88% | XXX | -1135% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -778% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 916% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CRISPR Therapeutics acquired XXX companies to date.
Last acquisition by CRISPR Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . CRISPR Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CRISPR Therapeutics founded? | CRISPR Therapeutics was founded in 2013. |
| Where is CRISPR Therapeutics headquartered? | CRISPR Therapeutics is headquartered in United States of America. |
| How many employees does CRISPR Therapeutics have? | As of today, CRISPR Therapeutics has 393 employees. |
| Who is the CEO of CRISPR Therapeutics? | CRISPR Therapeutics's CEO is Dr. Samarth Kulkarni, PhD. |
| Is CRISPR Therapeutics publicy listed? | Yes, CRISPR Therapeutics is a public company listed on NAS. |
| What is the stock symbol of CRISPR Therapeutics? | CRISPR Therapeutics trades under CRSP ticker. |
| When did CRISPR Therapeutics go public? | CRISPR Therapeutics went public in 2016. |
| Who are competitors of CRISPR Therapeutics? | Similar companies to CRISPR Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CRISPR Therapeutics? | CRISPR Therapeutics's current market cap is $3.1B |
| What is the current revenue of CRISPR Therapeutics? | CRISPR Therapeutics's last 12 months revenue is $39.4M. |
| What is the current revenue growth of CRISPR Therapeutics? | CRISPR Therapeutics revenue growth (NTM/LTM) is 143%. |
| What is the current EV/Revenue multiple of CRISPR Therapeutics? | Current revenue multiple of CRISPR Therapeutics is 38.0x. |
| Is CRISPR Therapeutics profitable? | Yes, CRISPR Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CRISPR Therapeutics? | CRISPR Therapeutics's last 12 months EBITDA is -$448M. |
| What is CRISPR Therapeutics's EBITDA margin? | CRISPR Therapeutics's last 12 months EBITDA margin is -1137%. |
| What is the current EV/EBITDA multiple of CRISPR Therapeutics? | Current EBITDA multiple of CRISPR Therapeutics is -3.3x. |
| What is the current FCF of CRISPR Therapeutics? | CRISPR Therapeutics's last 12 months FCF is -$227M. |
| What is CRISPR Therapeutics's FCF margin? | CRISPR Therapeutics's last 12 months FCF margin is -576%. |
| What is the current EV/FCF multiple of CRISPR Therapeutics? | Current FCF multiple of CRISPR Therapeutics is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
